跳至主要内容
临床试验/NCT02493348
NCT02493348
已完成
不适用

A Study of the Effect of Rhythmic Sensory Stimulation on Fibromyalgia

Mount Sinai Hospital, Canada1 个研究点 分布在 1 个国家目标入组 50 人2015年10月
适应症Fibromyalgia

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Fibromyalgia
发起方
Mount Sinai Hospital, Canada
入组人数
50
试验地点
1
主要终点
Change of Fibromyalgia symptoms and severity from baseline assessed by the Revised Fibromyalgia Impact Questionnaire (FIQ) at 6 weeks
状态
已完成
最后更新
7年前

概览

简要总结

Fibromyalgia is a chronic pain disorder associated with widespread pain that dramatically impacts patient's quality of life. The present research aims to determine the effectiveness of Rhythmic Sensory Stimulation with rhythmic gamma-frequency (30 - 120 Hz) acoustic-driven stimulation of mechanoreceptors in the body on the treatment of fibromyalgia. The proposed treatment involves 30 minutes of daily rhythmic vibroacoustic stimulation at gamma range, 5 days per week, for 5 weeks. Measures of pain severity, fibromyalgia symptoms, sleep quality, and depression, will be compared before and after treatment between the treatment and control groups. The results of the present study will help to better understand the effectiveness of Rhythmic Sensory Stimulation to the treatment of chronic pain disorders, such as fibromyalgia, and contribute to the development of future studies to investigate the neural driving effects of therapies based on Rhythmic Sensory Stimulation.

详细描述

Fibromyalgia is a chronic pain disorder associated with widespread pain that dramatically impacts patients' quality of life. Its exact cause has not yet been identified, however, recent studies indicate that fibromyalgia is associated with a significant imbalance of the connectivity within brain networks associated with pain, decreased functional connectivity in the descending pain-modulating system, and increased activity in the pain matrix related to central sensitization. It has been suggested that treatments that stimulate or induce coherent neuronal activity, and synchronize dysregulated brain circuitry, have significant benefits in improving pain management and enhancing patients' quality of life. An example of a non-invasive treatment that is thought to indirectly stimulate neuronal coherence is Rhythmic Sensory Stimulation (RSS) in gamma frequencies. RSS stimulates the mechanoreceptors in the body using gamma-frequency sounds (e.g., 40 Hz) by means of speakers in a chair. Previous research demonstrates significantly improved pain management in several pain conditions (e.g., rheumatoid arthritis, low-back pain, sports injuries); however, little is known about the effect of RSS with gamma-frequency sound stimulation on fibromyalgia. The use of RSS to treat fibromyalgia was first explored very recently and findings indicate that this treatment could be effective for individuals with fibromyalgia given that gamma-frequency sound stimulation indirectly stimulates neuronal coherence. Aim: The present study aims to examine the effects of gamma frequency rhythmic sensory stimulation on fibromyalgia symptoms. Treatment effectiveness will be assessed by examining whether sensory stimulation will produce clinically meaningful changes in fibromyalgia symptom severity and whether treatment response will differ between the two treatment parameters. Intervention: Fifty patients with a formal diagnosis of fibromyalgia were randomly assigned to two test groups. One group received vibrotactile stimulation from a continuous sine wave single-frequency stimulation (40 Hz) for 30 minutes, five days per week, over five weeks, concomitant with usual care. The second group completed the same treatment protocol but received different stimulation consisting of random and intermittent complex wave gamma-range vibrotactile stimulation. Measures of pain severity, fibromyalgia symptoms, sleep quality, and depression will be compared before and after treatment between the two groups. The results of the present study will help to better understand the effectiveness of RSS for treatment of chronic pain disorders, such as fibromyalgia, and contribute to the development of future studies to investigate the mechanisms underlying clinical responses to rhythmic sensory stimulation.

注册库
clinicaltrials.gov
开始日期
2015年10月
结束日期
2016年12月
最后更新
7年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Allan Gordon

Director of Wasser Pain Management Centre

Mount Sinai Hospital, Canada

入排标准

入选标准

  • Clinical diagnosis of fibromyalgia conducted by the medical staff at Wasser Pain Management Centre;
  • Ability to read and write English adequately;
  • Have satisfactory hearing bilaterally (self-reported);
  • Have the ability to operate the supplied device.

排除标准

  • Acute and active inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis, autoimmune disease);
  • Unstable medical or psychiatric illness;
  • History of psychosis, epilepsy, seizures;
  • Pregnancy or breast feeding;
  • Hemorrhaging or active bleeding;
  • Thrombosis, angina pectoris;
  • Heart diseases, such as hypotension, arrhythmia, pacemaker;
  • Substance abuse in the last year;
  • Recently prolapsed vertebral disc;
  • Recovering from a recent accident with back or neck injury.

结局指标

主要结局

Change of Fibromyalgia symptoms and severity from baseline assessed by the Revised Fibromyalgia Impact Questionnaire (FIQ) at 6 weeks

时间窗: Assessed at Week 0 (pre-intervention) and Week 6 (post-intervention)

The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes, based on a 10 point scale.

次要结局

  • Change of sleep quality from baseline assessed by the Pittsburgh Sleep Quality Index (PSQI) at 6 weeks(Assessed at Week 0 (pre-intervention) and Week 6 (post-intervention))
  • Change of depression severity from baseline assessed by the Patient Health Questionnaire-9 (PHQ-9) at 6 weeks(Assessed at Week 0 (pre-intervention) and Week 6 (post-intervention))
  • Change of pain severity from baseline assessed by Brief Pain Inventory - short form (BPI-SF) at 6 weeks(Assessed at Week 0 (pre-intervention) and Week 6 (post-intervention))
  • Change in general quality of life from baseline assessed by the Quality of Life Enjoyment and Satisfaction questionnaire (Q-LES-Q-SF) at 6 weeks(Assessed at Week 0 (pre-intervention) and Week 6 (post-intervention))

研究点 (1)

Loading locations...

相似试验